β‐amyloid burden is not associated with rates of brain atrophy

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Annals of Neurology

• Publication date

  2008-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/ana.21223PMID 17894374PMCID PMC2735194
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diagnostic and Statistical Manual of Mental Disorders

  2008cited by this paper
• Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report.

  2007cited by this paper
• Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide

  2007cited by this paper
• An estimate of the total worldwide societal costs of dementia in 2005

  2007cited by this paper
• Amyloid load and cerebral atrophy in Alzheimer's disease: An 11C‐PIB positron emission tomography study

  2006cited by this paper
• Rates of cerebral atrophy differ in different degenerative pathologies.

  2006cited by this paper
• Risk factors for progression of brain atrophy in aging

  2005cited by this paper
• Voxel-based morphometric comparison between early- and late-onset mild Alzheimer's disease and assessment of diagnostic performance of z score images.

  2005influential reference
• Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial

  2005cited by this paper
• Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease

  2005cited by this paper
• Neuropathological stageing of Alzheimer-related changes

  2004cited by this paper
• Apolipoprotein E epsilon 4 is a determinant for Alzheimer-type pathologic features in tauopathies, synucleinopathies, and frontotemporal degeneration.

  2004cited by this paper
• Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function.

  2004cited by this paper
• Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD

  2004cited by this paper
• Methodological considerations for measuring rates of brain atrophy

  2003cited by this paper
• Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease

  2003cited by this paper
• Neuropathology of Cognitively Normal Elderly

  2003cited by this paper
• Changes in premorbid brain volume predict Alzheimer’s disease pathology

  2003cited by this paper
• Stereologic assessment of the total cortical volume occupied by amyloid deposits and its relationship with cognitive status in aging and Alzheimer's disease.

  2002cited by this paper
• Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia

  2002cited by this paper
• Hippocampal volume as an index of Alzheimer neuropathology: Findings from the Nun Study

  2002cited by this paper
• A New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT

  2001cited by this paper
• FLAIR histogram segmentation for measurement of leukoaraiosis volume

  2001cited by this paper
• Quantification of histochemical staining by color deconvolution.

  2001cited by this paper
• Inheritance of the ApoE ε4 Allele Increases the Rate of Brain Atrophy in Dementia Patients

  1999cited by this paper
• Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse

  1999cited by this paper
• Alzheimer neuropathologic alterations in aged cognitively normal subjects.

  1999cited by this paper
• Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease.

  1999cited by this paper
• Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer’s Disease

  1999cited by this paper
• Inheritance of the ApoE epsilon4 allele increases the rate of brain atrophy in dementia patients.

  1999cited by this paper
• Examination of the validity of the hierarchical model of neuropathological staging in normal aging and Alzheimer’s disease

  1998cited by this paper
• Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease.

  1997cited by this paper
• Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease.

  1997cited by this paper
• The neuropathological diagnosis of Alzheimer's disease: clinical-pathological studies.

  1997cited by this paper
• The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI

  1997cited by this paper
• Hippocampal pathology reflects memory deficit and brain imaging measurements in Alzheimer's disease: clinicopathologic correlations using three sets of pathologic diagnostic criteria.

  1996cited by this paper
• Evolution of the neuropathology of Alzheimer's disease

  1996cited by this paper
• β-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease

  1996cited by this paper
• Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease.

  1996cited by this paper
• Interlaboratory Comparison of Neuropathology Assessments in Alzheimer's Disease: A Study of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD)

  1994cited by this paper
• A method for using MR to evaluate the effects of cardiovascular disease on the brain: the cardiovascular health study.

  1994cited by this paper
• Single-day apolipoprotein E genotyping.

  1994cited by this paper
• A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging.

  1993cited by this paper
• The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)

  1993cited by this paper
• Alzheimer's disease: the amyloid cascade hypothesis.

  1992influential reference
• Identification of normal and pathological aging in prospectively studied nondemented elderly humans.

  1992cited by this paper
• Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease

  1992cited by this paper
• The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)

  1991cited by this paper
• Diffuse type of senile plaques in the brains of Alzheimer-type dementia

  1988cited by this paper
• Alzheimer's disease and tau proteins.

  1986cited by this paper
• Amyloid plaque core protein in Alzheimer disease and Down syndrome.

  1985cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• The appropriateness of analysis of variance and multiple-comparison procedures.

  1983cited by this paper
• The appropriateness of analysis of variance and multiple-comparison procedures.

  1983cited by this paper
• A New Clinical Scale for the Staging of Dementia

  1982cited by this paper
• Letter: Congenital malformations and vinyl chloride.

  1975cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975cited by this paper
• Risk factors for progression of brain atrophy in aging Six-year follow-up of normal subjects

  year unknowncited by this paper

• Cumulative cognitive benefits and brain volume change with anti-amyloid therapies for Alzheimer’s disease

  2026cites this paper
• Associations between Structural Neuroimaging Markers and Neuropathology of Alzheimer's Disease.

  2026cites this paper
• Fluorescent Labeling Methods for Brain Structure Research

  2026cites this paper
• Lemborexant ameliorates tau-mediated sleep loss and neurodegeneration in males in a mouse model of tauopathy

  2025cites this paper
• Localization of Network-Level Atrophy in Preclinical Alzheimer’s Disease

  2025cites this paper
• Amyloid PET predicts atrophy in older adults without dementia: Results from the AMYPAD Prognostic & Natural History study

  2025cites this paper
• ApoE4 accelerates the condensate to amyloid transition of tau

  2025cites this paper
• Correlating retinal and choroidal vascular parameters with volumetric MRI in Alzheimer’s disease and amnestic mild cognitive impairment

  2025cites this paper
• Explainable Artificial Intelligence in Neuroimaging of Alzheimer’s Disease

  2025cites this paper
• Soluble Aβ pathology predicts neurodegeneration and cognitive decline independently on p‐tau in the earliest Alzheimer's continuum: Evidence across two independent cohorts

  2025cites this paper
• Neurobiological correlates of longitudinal grey matter volume changes in preclinical Alzheimer’s disease

  2025cites this paper
• Study on Interactive Effects of APOE ε4 and Tau Pathology on Cognitive Trajectories in Mild Cognitive Impairment

  2025cites this paper
• Reduced Cortical Thickness Correlates of Cognitive Dysfunction in Post-COVID-19 Condition: Insights from a Long-Term Follow-up

  2024cites this paper
• The characteristics of brain atrophy prior to the onset of Alzheimer’s disease: a longitudinal study

  2024cites this paper
• An emerging role for the gut microbiome in tauopathy

  2024cites this paper
• Functional Glial Activation Mediates Phenotypic Effects of APOEɛ4 and Sex in Alzheimer’s Disease

  2024cites this paper
• A bibliometric analysis of international publication trends in brain atrophy research (2008–2023)

  2024cites this paper
• Modeling Alzheimer’s disease using human cell derived brain organoids and 3D models

  2024cites this paper
• Brain volume change following anti-amyloid β immunotherapy for Alzheimer's disease: amyloid-removal-related pseudo-atrophy.

  2024cites this paper
• Live-cell visualization of tau aggregation in human neurons

  2024cites this paper
• Microglial responses partially mediate the effect of Aβ on cognition in Alzheimer's disease

  2024cites this paper
• Associations of sleep disorders with all-cause MCI/dementia and different types of dementia – clinical evidence, potential pathomechanisms and treatment options: A narrative review

  2024cites this paper
• Current insights into apolipoprotein E and the immune response in Alzheimer's disease

  2024cites this paper
• Hacia un diagnóstico diferencial entre demencias corticales: una reseña de literatura de estudios comparativos

  2023cites this paper
• Neuronal APOE4 removal protects against tau-mediated gliosis, neurodegeneration and myelin deficits

  2023cites this paper
• Pathology of neurodegenerative disease for the general neurologist

  2023cites this paper
• Schlaf und Demenz

  2023cites this paper
• Sulfatide Deficiency, an Early Alzheimer’s Lipidomic Signature, Causes Brain Ventricular Enlargement in the Absence of Classical Neuropathological Hallmarks

  2022cites this paper
• Amyloid-β42 oligomeric forms: AFM nanoscale structural characterization and impact on long-term memory of young and aged zebrafish.

  2022cites this paper
• Different Profiles of Spatial Navigation Deficits In Alzheimer’s Disease Biomarker-Positive Versus Biomarker-Negative Older Adults With Amnestic Mild Cognitive Impairment

  2022cites this paper
• Dissecting the complexities of Alzheimer disease with in vitro models of the human brain

  2021cites this paper
• Tau Is Truncated in Five Regions of the Normal Adult Human Brain

  2021cites this paper
• Brain aging mechanisms with mechanical manifestations

  2021cites this paper
• Association of Osteoarthritis With Changes in Structural Neuroimaging Markers Over Time Among Non-demented Older Adults

  2021cites this paper
• Association of CD2AP neuronal deposits with Braak neurofibrillary stage in Alzheimer’s disease

  2021cites this paper
• Cerebral Blood Flow Predicts Conversion of Mild Cognitive Impairment into Alzheimer’s Disease and Cognitive Decline: An Arterial Spin Labeling Follow-up Study

  2021cites this paper
• ApoE4 inhibition of VMAT2 in the locus coeruleus exacerbates Tau pathology in Alzheimer’s disease

  2021cites this paper
• Studying APOE ɛ4 Allele Dose Effects with a Univariate Morphometry Biomarker

  2021cites this paper
• The AD tau core spontaneously self-assembles and recruits full-length tau to filaments

  2021cites this paper
• Neuronal loss and microgliosis are restricted to the core of Aβ deposits in mouse models of Alzheimer's disease

  2021cites this paper
• Relationship Between General Cognition, Visual Assessed Cortical Atrophy, and Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease: A Cross-Sectional Study from a Chinese PUMCH Cohort

  2021cites this paper
• Different patterns of β-amyloid deposition in patients with Alzheimer's disease according to the presence of mild parkinsonism.

  2021cites this paper
• Cerebral Blood Flow Predicts Conversion of Mild Cognitive Impairment into Alzheimer’s Disease and Cognitive Decline: An ASL Follow-up Study

  2021cites this paper
• Effect Modifiers of TDP-43-Associated Hippocampal Atrophy Rates in Patients with Alzheimer’s Disease Neuropathological Changes

  2020cites this paper
• Aβ Imaging in Aging, Alzheimer’s Disease, and Other Neurodegenerative Conditions

  2020cites this paper
• Insulin resistance and Alzheimer’s disease

  2020cites this paper
• The Role of Apolipoprotein E in Alzheimer Disease: From Therapy to Mechanism

  2020cites this paper
• Clusterin ameliorates tau pathology in vivo by inhibiting fibril formation

  2020cites this paper
• Neuropathologic basis of in vivo cortical atrophy in the aphasic variant of Alzheimer's disease

  2020influential citation
• β-amyloid: the known unknowns.

  2020cites this paper
• Correlation of OCTA and Volumetric MRI in Mild Cognitive Impairment and Alzheimer's Disease.

  2019cites this paper
• COMPARISON OF N-HETEROCYCLIC AMINE LIGANDS FOR POTENTIAL APPLICATION AS ALZHEIMER’S DISEASE THERAPUETIC AGENTS

  2019cites this paper
• Delineating the topography of amyloid-associated cortical atrophy in Down syndrome.

  2019cites this paper
• Usefulness of CSF Biomarkers in Predicting the Progression of Amnesic and Nonamnesic Mild Cognitive Impairment to Alzheimer's Disease.

  2019cites this paper
• Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model

  2019cites this paper
• Braak neurofibrillary tangle staging prediction from in vivo MRI metrics

  2019cites this paper
• The role of capillary pericytes in cerebral blood flow changes during ischaemia and in Alzheimer's disease

  2019cites this paper
• Mechanisms of Microglia Mediated Apolipoprotien E Neurotoxicity

  2019cites this paper
• In vivo hippocampal subfield shape related to TDP-43, amyloid beta, and tau pathologies.

  2019cites this paper
• Beta amyloid deposition maps onto hippocampal and subiculum atrophy in dementia with Lewy bodies.

  2019cites this paper
• Topographical Heterogeneity of Alzheimer’s Disease Based on MR Imaging, Tau PET, and Amyloid PET

  2019cites this paper
• Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies

  2019cites this paper
• Neurochemical Aspects of Neurological Disorders

  2019cites this paper
• The basis of cellular and regional vulnerability in Alzheimer’s disease

  2019cites this paper
• Isorhynchophylline Ameliorates Cognitive Impairment via Modulating Amyloid Pathology, Tau Hyperphosphorylation and Neuroinflammation: Studies in a Transgenic Mouse Model of Alzheimer's Disease.

  2019cites this paper
• Applying surface-based hippocampal morphometry to study APOE-E4 allele dose effects in cognitively unimpaired subjects

  2019cites this paper
• Characteristic asymmetric limbic and anterior temporal atrophy in demented patients with pathologically confirmed argyrophilic grain disease

  2019cites this paper
• Correlations Between Cerebrospinal Fluid Biomarkers Concentration and Severity of Cognitive Impairment in Alzheimer Disease

  2019cites this paper
• Current knowledge on the relationship between ApoE and Alzheimer’s disease

  2018cites this paper
• Development of Multifunctional Molecules as Potential Therapeutic Candidates for Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis in the Last Decade.

  2018cites this paper
• A Retrospective Belgian Multi-Center MRI Biomarker Study in Alzheimer’s Disease (REMEMBER)

  2018cites this paper
• Amyloid, tau, pathogen infection and antimicrobial protection in Alzheimer’s disease –conformist, nonconformist, and realistic prospects for AD pathogenesis

  2018cites this paper
• The role of myelin damage in Alzheimer’s disease pathology

  2018cites this paper
• Reactive astrocytes in Alzheimer's disease: A double-edged sword.

  2018cites this paper
• Regional Distribution, Asymmetry, and Clinical Correlates of Tau Uptake on [18F]AV-1451 PET in Atypical Alzheimer’s Disease

  2018cites this paper
• Detecting and tracking early neurodegeneration in familial Alzheimer's disease

  2018cites this paper
• Effets de l’administration de tétrahydrobioptérine en condition physiologique et pathologique : De la neurobiologie au comportement

  2018cites this paper
• Implication des systèmes de dégradation cellulaire, de la protéine VCP et de nouvelles molécules sur le métabolisme de l’APP : aspects fondamentaux et appliqués à la maladie d’Alzheimer

  2018cites this paper
• Imaging and Molecular Mechanisms of Alzheimer’s Disease: A Review

  2018cites this paper
• Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology

  2018cites this paper
• Semiquantitation of Axonal Injury in Traumatically Damaged Brains Using Color Deconvolution

  2017cites this paper
• Pathology of Neurodegenerative Diseases.

  2017cites this paper
• Application of calibrated fMRI in Alzheimer's disease

  2017cites this paper
• Radiological-Pathological Correlation in Alzheimer’s Disease: Systematic Review of Antemortem Magnetic Resonance Imaging Findings

  2017cites this paper
• Cognitive Frailty: Mechanisms, Tools to Measure, Prevention and Controversy.

  2017cites this paper
• Magnetic resonance imaging of resting cerebral oxygen metabolism : applications in Alzheimer’s disease

  2017cites this paper
• Functional Amyloids and their Possible Influence on Alzheimer Disease

  2017cites this paper
• Differential microstructural and morphological abnormalities in mild cognitive impairment and Alzheimer's disease: Evidence from cortical and deep gray matter

  2017cites this paper
• ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy

  2017cites this paper
• Energy and the Alzheimer brain

  2017influential citation
• APP/A&bgr; structural diversity and Alzheimer's disease pathogenesis

  2017cites this paper
• Longitudinal brain structural changes in preclinical Alzheimer's disease

  2017cites this paper
• Neurochemical Aspects of β-Amyloid Cascade Hypothesis for Alzheimer’s Disease: A Critical Evaluation

  2017cites this paper
• Ketogenic Diet and Metabolic Therapies : Expanded Roles in Health and Disease

  2017cites this paper
• Risk and protective factors for structural brain ageing in the eighth decade of life

  2017cites this paper
• Experimental Transmission of Alzheimer's Disease Endophenotypes to Murine and Primate Models

  2016influential citation
• Relationship of regional brain β-amyloid to gait speed

  2016cites this paper
• PET Imaging of Copper Trafficking in a Mouse Model of Alzheimer Disease

  2016cites this paper
• Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.

  2016cites this paper
• [18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration

  2016cites this paper